Notice of Closed Meeting, 26888-26889 [2024-07961]

Download as PDF 26888 Federal Register / Vol. 89, No. 74 / Tuesday, April 16, 2024 / Notices federal procurement of products that either intentionally or unintentionally contain PFAS while minimizing any unnecessary burdens on our industry and logistics partners. khammond on DSKJM1Z7X2PROD with NOTICES III. Request for Operational Information GSA seeks responses to the questions listed below. Please explain the reasoning behind your responses in detail. Also, please provide any data, studies, or other evidence that supports your response. In your response please include your contact information, your business socio-economic category if applicable, and a little bit about your business (such as if you represent a manufacturer, distributor, reseller, or other). To help GSA review comments efficiently, identify the question to which you are responding by its associated number and letter (e.g., ‘‘III.3a’’) or whether you are commenting on a topic not listed below. 1. Aside from a product’s ecolabel, are there other ways to identify if a product contains PFAS? 2. Considering GSA’s goal to reduce products containing PFAS, what product categories have the greatest opportunity for GSA to reduce or eliminate PFAS exposure? 3. What should GSA consider in terms of defining if a product has reduced or eliminated PFAS? 4. What product areas should GSA exclude at this time and why? 5. Are there unintended impacts GSA should anticipate? a. If so, what mitigation strategies should GSA consider? 6. What is the potential impact on domestic manufacturing if GSA establishes PFAS reduction requirements that reduce or prohibit PFAS, or eliminate them entirely? 7. What limitations exist for you to identify PFAS in the products that you offer? 8. Would your answers to questions #6 and #7 be different if only intentionally added PFAS (or when a PFAS containing chemical is included in a product that serves an intended function in the product) was the focus of this inquiry? 9. What is the potential impact on small businesses including socioeconomic small businesses if GSA establishes PFAS reduction requirements or prohibited PFAS entirely? 10. How long should GSA give contractors to reduce PFAS? 11. What type of exception process should GSA consider? VerDate Sep<11>2014 19:09 Apr 15, 2024 Jkt 262001 12. What information is readily available for you to determine if your products contain PFAS chemicals? a. If there is not information readily available, what type of tools would help you determine if PFAS is present (e.g., supply chain mapping, specific ecolabels, etc.) 13. Would it be more impactful for GSA to target a specific product type or chemical signature in products to meet the goal of reducing or eliminating PFAS? 14. Are there existing industry manufacturing standards or oversight that address PFAS reduction or elimination? will take place from 12:30 p.m. to 5:15 p.m. (EDT). The meetings will take place online, and anyone can register to attend at https://www.fdlp.gov/about/ events-and-conferences/2024depository-library-council-virtualmeeting. Closed captioning will also be provided. The purpose is to discuss matters affecting the Federal Depository Library Program and its transition to a digital program. All sessions are open to the public. DATES: May 2, 2024. IV. Request for Economic Data and Consumer Research Aside from the questions listed above, GSA also seeks to better understand the bigger picture regarding what industry changes are in fact feasible from an economic perspective. GSA seeks economic data and consumer research to help increase its understanding of the market. In your response please consider some of the questions highlighted below. You do not have to answer all of these in your response. The intent of the following are simply things to consider. 1. What will the estimated costs be to either reduce or eliminate PFAS within your industry? 2. Is there a large price differential between a product that contains PFAS and an alternative product? 3. How would a reduction or elimination of PFAS containing products impact your company’s ability to compete? 4. To what extent is your industry already moving to better understand and reduce the presence of PFAS in products as a result of broader market forces or policies being considered or enacted by entities other than the federal government? BILLING CODE 1520–01–P Jeffrey A. Koses, Senior Procurement Executive, Office of Governmentwide Policy, U.S. General Services Administration. [FR Doc. 2024–07927 Filed 4–15–24; 8:45 am] BILLING CODE 6820–61–P GOVERNMENT PUBLISHING OFFICE Depository Library Council Meeting AGENCY: U.S. Government Publishing Office. ACTION: Notice of meeting. The Depository Library Council (DLC) will meet virtually on Thursday, May 2, 2024. The sessions SUMMARY: PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 Hugh Nathanial Halpern, Director, U.S. Government Publishing Office. [FR Doc. 2024–08040 Filed 4–15–24; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— PAR 20–280, Cooperative Research Agreements Related to the World Trade Center Health Program (U01); RFA–OH– 24–002, Exploratory/Developmental Grants on Lifestyle Medicine Research Related to the World Trade Center Health Program (R21); RFA–OH–24–003, Exploratory/Developmental Grants Related to the World Trade Center Survivors (R21-No Applications with Responders Accepted); and RFA–OH– 24–004, World Trade Center Health Program Mentored Research Scientist Career Development Award (K01). Dates: May 28–30, 2024. Times: 11 a.m.–6 p.m., EDT. Place: Video-Assisted Meeting. Agenda: To review and evaluate grant applications. E:\FR\FM\16APN1.SGM 16APN1 Federal Register / Vol. 89, No. 74 / Tuesday, April 16, 2024 / Notices For Further Information Contact: Laurel Garrison, M.P.H., Scientific Review Officer, Office of Extramural Programs, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 5555 Ridge Avenue, Cincinnati, Ohio 45213. Telephone: (513) 533–8324; Email: LGarrison@cdc.gov. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–07961 Filed 4–15–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–1819–N] Public Meeting on June 25, 2024 Regarding New and Reconsidered Clinical Diagnostic Laboratory Test Codes for the Clinical Laboratory Fee Schedule for Calendar Year 2025 Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Notice. AGENCY: This notice announces a public meeting to receive comments and recommendations (including data on which recommendations are based) on the appropriate basis for establishing payment amounts for new or substantially revised Healthcare Common Procedure Coding System codes being considered for Medicare payment under the Clinical Laboratory Fee Schedule for calendar year 2025. This meeting also provides a forum for those who submitted certain reconsideration requests regarding final determinations made last year on new test codes and for the public to provide comment on the requests. DATES: Clinical Laboratory Fee Schedule (CLFS) Annual Public Meeting Date: The public meeting is scheduled for Tuesday, June 25, 2024 from 9:00 a.m. khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 19:09 Apr 15, 2024 Jkt 262001 to 5:00 p.m., Eastern Daylight Time (E.D.T.). Deadline for Submission of Presentations and Written Comments: All presenters for the CLFS Annual Public Meeting must register and submit their presentations electronically to our CLFS dedicated email box, CLFS_ Annual_Public_Meeting@cms.hhs.gov, by May 30, 2024 at 5:00 p.m., E.D.T. All written comments (non-presenter comments) must also be submitted electronically to our CLFS dedicated email box, CLFS_Annual_Public_ Meeting@cms.hhs.gov, by May 30, 2024, at 5:00 p.m., E.D.T. Any presentations or written comments received after that date and time will not be included in the meeting and will not be reviewed. Deadline for Submitting Requests for Special Accommodations: Requests for special accommodations must be received no later than May 30, 2024 at 5:00 p.m. E.D.T. Publication of Proposed Determinations: We intend to publish our proposed determinations for new test codes and our proposed determinations for reconsidered codes (as described later in section II, ‘‘Format’’ of this notice) for calendar year 2025 by early September 2024. Deadline for Submission of Written Comments Related to Proposed Determinations: Comments in response to the proposed determinations will be due by early October 2024. ADDRESSES: The CLFS Annual Public Meeting will be held virtually and inperson at the Centers for Medicare & Medicaid Services (CMS), Central Building, 7500 Security Boulevard, Baltimore, Maryland 21244–1850. Where to Submit Written Comments: Interested parties should submit all written comments on presentations and proposed determinations electronically to our CLFS dedicated email box, CLFS_ Annual_Public_Meeting@cms.hhs.gov (the specific date for the publication of these determinations and the deadline for submitting comments regarding these determinations will be published on the CMS website). FOR FURTHER INFORMATION CONTACT: Rasheeda Arthur, (410) 786–3434. The CLFS Policy Team and submit all inquiries to the CLFS dedicated email box, CLFS_Annual_Public_Meeting@ cms.hhs.gov with the subject entitled ‘‘CLFS Annual Public Meeting Inquiry.’’ SUPPLEMENTARY INFORMATION: I. Background Section 531(b) of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) (Pub. L. 106–554) required PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 26889 the Secretary of the Department of Health and Human Services (the Secretary) to establish procedures for coding and payment determinations for new clinical diagnostic laboratory tests under part B of title XVIII of the Social Security Act (the Act) that permit public consultation in a manner consistent with the procedures established for implementing coding modifications for International Classification of Diseases, Tenth Revision, Clinical Modification (ICD–10–CM). The procedures and Clinical Laboratory Fee Schedule (CLFS) public meeting announced in this notice for new tests are in accordance with the procedures published on November 23, 2001 in the Federal Register (66 FR 58743) to implement section 531(b) of BIPA. Section 942(b) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108–173) added section 1833(h)(8) of the Act. Section 1833(h)(8)(A) of the Act requires the Secretary to establish by regulation procedures for determining the basis for, and amount of, payment for any clinical diagnostic laboratory test (CDLT) for which a new or substantially revised Healthcare Common Procedure Coding System (HCPCS) code is assigned on or after January 1, 2005. A code is considered to be substantially revised if there is a substantive change to the definition of the test or procedure to which the code applies (for example, a new analyte or a new methodology for measuring an existing analyte-specific test). (See section 1833(h)(8)(E)(ii) of the Act and 42 CFR 414.502)). Section 1833(h)(8)(B) of the Act sets forth the process for determining the basis for, and the amount of, payment for new tests. Pertinent to this notice, sections 1833(h)(8)(B)(i) and (ii) of the Act require the Secretary to make available to the public a list that includes any such test for which establishment of a payment amount is being considered for a year and, on the same day that the list is made available, cause to have published in the Federal Register notice of a meeting to receive comments and recommendations (including data on which recommendations are based) from the public on the appropriate basis for establishing payment amounts for the tests on such list. This list of codes for which the establishment of a payment amount under the CLFS is being considered for calendar year (CY) 2025 will be posted on the Centers for Medicare & Medicaid Services (CMS) website concurrent with the publication of this notice and may be updated prior to the CLFS Annual Public Meeting. The E:\FR\FM\16APN1.SGM 16APN1

Agencies

[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Pages 26888-26889]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07961]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the 
following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended, and the Determination of the Director, Office of 
Strategic Business Initiatives, Office of the Chief Operating Officer, 
CDC, pursuant to Public Law 92-463. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.
    Name of Committee: Disease, Disability, and Injury Prevention and 
Control Special Emphasis Panel (SEP)--PAR 20-280, Cooperative Research 
Agreements Related to the World Trade Center Health Program (U01); RFA-
OH-24-002, Exploratory/Developmental Grants on Lifestyle Medicine 
Research Related to the World Trade Center Health Program (R21); RFA-
OH-24-003, Exploratory/Developmental Grants Related to the World Trade 
Center Survivors (R21-No Applications with Responders Accepted); and 
RFA-OH-24-004, World Trade Center Health Program Mentored Research 
Scientist Career Development Award (K01).
    Dates: May 28-30, 2024.
    Times: 11 a.m.-6 p.m., EDT.
    Place: Video-Assisted Meeting.
    Agenda: To review and evaluate grant applications.

[[Page 26889]]

    For Further Information Contact: Laurel Garrison, M.P.H., 
Scientific Review Officer, Office of Extramural Programs, National 
Institute for Occupational Safety and Health, Centers for Disease 
Control and Prevention, 5555 Ridge Avenue, Cincinnati, Ohio 45213. 
Telephone: (513) 533-8324; Email: [email protected].
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-07961 Filed 4-15-24; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.